Fidelity Investments
TSHA icon

Fidelity Investments’s Taysha Gene Therapies TSHA Stock Holding History

Fidelity Investments’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.8M Sell
13,336,413
-984,842
-7% -$5.83M ﹤0.01% 1261
2026
Q1 		$64M Buy
14,321,255
+792,889
+6% +$3.69M ﹤0.01% 1343
2025
Q4 		$74.4M Sell
13,528,366
-1,065,046
-7% -$5.17M ﹤0.01% 1292
2025
Q3 		$47.7M Sell
14,593,412
-1,034,410
-7% -$2.93M ﹤0.01% 1452
2025
Q2 		$36.1M Sell
15,627,822
-4,132
-0% -$8.98K ﹤0.01% 1500
2025
Q1 		$21.7M Sell
15,631,954
-733,710
-4% -$1.23M ﹤0.01% 1646
2024
Q4 		$28.3M Sell
16,365,664
-2,312,863
-12% -$4.8M ﹤0.01% 1608
2024
Q3 		$37.5M Sell
18,678,527
-2,532,109
-12% -$5.56M ﹤0.01% 1490
2024
Q2 		$47.5M Buy
21,210,636
+1,099,919
+5% +$3.2M ﹤0.01% 1329
2024
Q1 		$57.7M Sell
20,110,717
-2,328,407
-10% -$4.85M ﹤0.01% 1276
2023
Q4 		$39.7M Sell
22,439,124
-2,088,677
-9% -$4.16M ﹤0.01% 1381
2023
Q3 		$77.5M Buy
24,527,801
+23,378,974
+2,035% +$43.7M 0.01% 1084
2023
Q2 		$759K Sell
1,148,827
-1,938,511
-63% -$1.4M ﹤0.01% 2544
2023
Q1 		$2.46M Sell
3,087,338
-117,584
-4% -$152K ﹤0.01% 2320
2022
Q4 		$7.24M Sell
3,204,922
-80,861
-2% -$164K ﹤0.01% 2014
2022
Q3 		$6.34M Sell
3,285,783
-9,906
-0.3% -$36K ﹤0.01% 2086
2022
Q2 		$12.3M Buy
3,295,689
+868
+0% +$3.44K ﹤0.01% 1861
2022
Q1 		$21.5M Sell
3,294,821
-985,673
-23% -$7.37M ﹤0.01% 1754
2021
Q4 		$49.9M Sell
4,280,494
-1,478,180
-26% -$22.3M ﹤0.01% 1422
2021
Q3 		$107M Buy
5,758,674
+71,058
+1% +$1.35M 0.01% 1075
2021
Q2 		$121M Buy
5,687,616
+23,401
+0.4% +$539K 0.01% 1041
2021
Q1 		$115M Hold
5,664,215
– – 0.01% 1008
2020
Q4 		$148M Buy
5,664,215
+1,456,641
+35% +$31.4M 0.01% 869
2020
Q3 		$90.1M Buy
+4,207,574
New +$99M 0.01% 957

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments's TSHA Position: Q2 2026 in Review

Fidelity Investments reduced its Taysha Gene Therapies (TSHA) stake by 6.9% in Q2 2026, selling an estimated $5.83M and leaving 13,336,413 shares worth $90.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1261.

Fidelity Investments first reported a position in TSHA in Q3 2020 and has held it in 24 quarters since. The position peaked at $148M in Q4 2020. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Fidelity Investments held 13,336,413 shares of Taysha Gene Therapies worth $90.8M as of Q2 2026.
  • Fidelity Investments sold 984,842 Taysha Gene Therapies shares in Q2 2026, an estimated $5.83M.
  • Taysha Gene Therapies made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1261 holding.
  • Fidelity Investments first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 24 quarters since.
  • Fidelity Investments's Taysha Gene Therapies position peaked at $148M in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.